CSS
TARA icon

Cubist Systematic Strategies’s Protara Therapeutics TARA Stock Holding History

Cubist Systematic Strategies’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19,679
Closed -$59.6K – 3544
2025
Q2 		$59.6K Buy
+19,679
New +$67.9K ﹤0.01% 2767

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Cubist Systematic Strategies's TARA Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Protara Therapeutics (TARA) in Q3 2025, closing a stake of 19,679 shares — an estimated $59.6K sold.

Cubist Systematic Strategies first reported a position in TARA in Q2 2025 and held it in 1 quarter. The position peaked at $59.6K in Q2 2025. 81 funds tracked by Wall St. Rank hold TARA as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining Protara Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 19,679 Protara Therapeutics shares in Q3 2025, an estimated $59.6K.
  • Cubist Systematic Strategies first reported a position in Protara Therapeutics in Q2 2025 and held it in 1 quarter.
  • Cubist Systematic Strategies's Protara Therapeutics position peaked at $59.6K in Q2 2025.
  • 81 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.